Compare DexCom, Inc. (DXCM) vs General Mills, Inc. (GIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs General Mills, Inc. — how do they compare? DexCom, Inc. trades at $90.64 (market cap $33.79B), while General Mills, Inc. trades at $37.93 (market cap $20.24B). The key difference: DexCom, Inc. is the larger of the two by market cap, and General Mills, Inc. pays a 6.43% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | GIS | |
|---|---|---|
Market Cap | $33.79B | $20.24B |
Sector | Health | Consumer Staples |
52-Week High | $89.53 | $51.11 |
52-Week Low | $54.84 | $32.17 |
Enterprise Value | $33.24B | $33.73B |
Dividend Yield | — | 6.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $91.00, up 3.82% today and near its 52-week high, with bullish technical signals from moving averages and strong fundamentals. Recent Q2 2026 earnings beat expectations with EPS of $0.70 versus $0.61 expected, driven by 13% revenue growth and margin expansion. The company raised full-year 2026 guidance, reflecting robust demand for continuous glucose monitors.
The outlook is positive due to sustained revenue growth, profitability improvements, and analyst consensus favoring buys. Risks include competitive pressures and potential regulatory scrutiny, but institutional ownership trends and earnings momentum support a constructive view for investors seeking exposure to medical technology.
General Mills (GIS) trades at $38.21, up 2.55% today, with a bullish technical signal from moving averages but mixed oscillators. Recent earnings show volatility, beating estimates in Q3 2025 and Q2 2026 but missing in Q4 2025. Revenue has declined from $20.1B in 2023 to $19.5B in 2025, with net income margin turning negative at -0.48% for 2026. The company maintains a dividend and is pursuing cost savings initiatives, while debt-to-asset ratio has risen to 45% in 2025.
Outlook is cautious; the stock offers a low P/E of 9.23 and dividend income, but faces headwinds from weak sales, margin pressure, and high debt. Analyst consensus is mixed with 22% buy, 61% hold ratings. Key risks include competitive pressures and execution of turnaround plans. Investors should weigh valuation appeal against fundamental challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About General Mills, Inc.
General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.
Read more on GIS →
